Nature Medicine, Published online: 08 January 2025; doi:10.1038/s41591-024-03455-z
KRAS mutations are ubiquitous in pancreatic adenocarcinomas (PDACs) and are associated with poor outcomes. We leveraged a cohort of 2,336 PDAC tumors to characterize genomic subtypes and their prognostic correlates across clinical stages. A key finding is that shallow copy gains in KRAS mutant alleles are common and indicate unfavorable prognosis.
